We have one of the largest specialist biotech teams in Europe supporting global biotech companies at all stages of development, innovation, and growth. Our clients are diverse and include therapeutics companies, suppliers of research tools, companion diagnostics, and other in vitro diagnostics and bio information solutions. Our expertise extends to broader applications of biotech across environmental, industrial, and agri-biotech.
With legal expertise grounded in scientific know-how, our support incorporates company formation, spin-out accelerator programmes, venture capital fundraisings, licensing and collaborations, clinical trials, and strategic alliances in addition to accessing capital markets and deploying intellectual property rights.
Clients value our long-held industry connections and our specialist sector expertise. Our global team is embedded in this industry with experience across many technologies, including vaccines, therapeutic proteins, monoclonal antibodies, immune-oncology, and cell-based therapies, gene therapies, and tissue-engineered products.
We are chosen by renowned biotech companies for our expertise in negotiating on pivotal IP licensing deals, resolving disputes with strategic partners, dealing with data privacy issues and avoiding competition/anti-trust risks. With our support, they push innovation boundaries and exploit commercial opportunities while remaining secure within relevant regulatory regimes.
We advised Apollo Therapeutics in their USD226.5 million series C fundraising. Apollo aims to advance pipeline programs through clinical development and further fund the company’s drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions, which include The Institute of Cancer Research.
Press releaseA US based company, involved in the development of new therapies for patients with severe neurological diseases affecting movement, in a clinical study involving sensitive genetic data.
Aktuelle News & Insights
Reporting clinical trial results to the market
von mehreren Autoren
UK government launches new Regulatory Innovation Office to reduce red tape
von Debbie Heywood
Licensing the Cabilly antibody manufacturing patents: are royalties payable on post-expiry sales?
von Charlie Adams und Adrian Toutoungi
Biotech acquisition trend: radiopharmaceuticals
von Adrian Toutoungi
Künstlich intelligente Medizinprodukte: Je besser das Produkt, desto schwieriger die Konformitätsbewertung?